---
title: "Expedition Therapeutics’ $115M Series B: General Atlantic Bets on COPD DPP1"
description: "General Atlantic led Expedition’s oversubscribed $115M Series B as the biotech dosed the first patient in a global Phase 2 COPD trial of EXPD-101 — a China-sourced NewCo twist."
date: 2026-08-05T00:00:00.000Z
tags: ["2026-vc-news", "startup-funding", "venture-capital", "biotech", "healthcare"]
source: https://venturecapitaltracker.com/2026-expedition-therapeutics-115m-series-b-copd
---

# Expedition Therapeutics’ $115M Series B: General Atlantic Bets on COPD DPP1

> General Atlantic led Expedition’s oversubscribed $115M Series B as the biotech dosed the first patient in a global Phase 2 COPD trial of EXPD-101 — a China-sourced NewCo twist.

**Expedition Therapeutics** closed an oversubscribed **$115 million Series B** on **August 5, 2026**, led by **General Atlantic**, with **RA Capital**, **Vivo Capital**, and a deep returning life-sciences syndicate. The same day, Expedition said the **first patient was dosed** in a global Phase 2 COPD trial of **EXPD-101**, a next-generation DPP1 inhibitor. Earlier August VCT roundups flagged this deal as a coverage gap — this is the deep dive.

## Key facts

| Field | Detail |
| --- | --- |
| Company | Expedition Therapeutics (San Francisco) |
| Round | $115M Series B (oversubscribed) |
| Date | August 5, 2026 |
| Lead | General Atlantic (Brett Zbar joins board) |
| Key participants | RA Capital, Vivo Capital + full existing syndicate |
| Lead asset | EXPD-101 — oral once-daily DPP1 inhibitor for COPD |
| Clinical status | First patient dosed, global randomized Phase 2 |
| Structure note | Asset in-licensed from Fosun Pharma (China NewCo pattern) |
| Prior | ~$165M Series A disclosed Oct 2025 (Endpoints) |

## Who uses the product — and for what job

**Near-term users:** clinical investigators and COPD trial participants across North/South America, Europe, and Asia (~600-patient Phase 2 described in Endpoints coverage; primary completion listed toward summer 2028 on public registries).

**Eventual users (if approved):** patients and pulmonologists treating COPD where **neutrophilic inflammation** drives exacerbations — a mechanism current symptom-management therapies do not fully address, per company and investigator commentary.

**Job today:** generate Phase 2 evidence that selective DPP1 inhibition improves outcomes enough to justify Phase 3 capital. Expedition claims first-mover status on a **global randomized Phase 2 DPP1 COPD trial**.

## Why now

- COPD remains a top global killer; standard of care still leaves inflammatory progression under-treated.
- DPP1 (dipeptidyl peptidase 1) sits upstream of neutrophil serine proteases — a mechanistic bet biotech capital understands how to price at Phase 2.
- China-sourced assets + Western clinical development (**NewCo**) have become a repeatable financing pattern; Expedition is one of ~19 such NewCos Endpoints tracked since early 2025.
- Phase 1 claimed clean enough PK/safety for once-daily oral dosing — the classic Series B trigger for a clinical biotech.

## Why General Atlantic — portfolio fit

General Atlantic manages ~**$129B AUM** (as of Jun 30, 2026, per its Expedition release) across growth equity and adjacent strategies. Life sciences under Zbar buys **inflection assets** with global development plans — not seed discovery platforms.

**Likely founder rationale:** a lead that can write a nine-figure clinical check, put a life-sciences MD on the board, and sit comfortably next to RA Capital / Novo / Forbion / Sanofi Ventures — the syndicate already fluent in NewCo COPD risk.

| Dimension | Fit |
| --- | --- |
| Stage | Phase 2 clinical financing |
| Thesis | Differentiated respiratory/inflammation asset |
| Geography | U.S. NewCo + global trial footprint |
| Structure | China in-license + Western development |

We do **not** currently list General Atlantic as a `/fund/` page — investor names are primary-sourced from company/GA materials.

## Competitive map

| Player / path | Lane |
| --- | --- |
| Existing COPD SoC (LABA/LAMA/ICS, biologics subsets) | Symptom / phenotype management; different MoA |
| Other DPP1 / neutrophil-pathway programs | Same biology race; Expedition claims global Ph2 first |
| Broader anti-inflammatory pipelines | Crowded; differentiation is oral DPP1 + COPD focus |
| Pure China domestic developers | Different regulatory/commercial path |

## Market signal

**$115M oversubscribed at first-patient-in** is the biotech market paying for a **clear clinical plan**, not an AI slogan. Absence of a disclosed valuation means you should underwrite dilution and Phase 2 risk — not invent a post-money for memos.

## When not to use this as a template

- Wrong if you treat NewCo in-licensing as “de-risked” — IP, CMC, and cross-border diligence still bite.
- Wrong if Phase 1 tolerability is equated with Phase 2 efficacy.
- Wrong if you compare this round to SaaS ARR multiples.

## Practical takeaway

- **Founders (biotech):** Time the raise to a real clinical milestone (FPI), then stack a specialist lead + crossover life-sciences book.
- **Investors:** Underwrite neutrophil COPD biology and China-license terms as carefully as enrollment speed.
- **Operators / scouts:** Watch Phase 2 endpoints and exacerbation rates — that is the binary, not the press release.

### Sources

1. Expedition Therapeutics (Aug 5, 2026): https://expeditiontx.com/news/expedition-therapeutics-announces-oversubscribed-115-million-series-b-financing-to-advance-next-generation-dpp1-inhibitor-for-copd/
2. General Atlantic media page: https://www.generalatlantic.com/media-article/expedition-therapeutics-announces-oversubscribed-115-million-series-b-financing-to-advance-next-generation-dpp1-inhibitor-for-copd/
3. Endpoints News (NewCo context): https://endpoints.news/expedition-gets-another-115m-for-its-twist-on-china-newco-model/
4. Related: [/2026-august-9-10-investment-news-chips-infra-biotech](/2026-august-9-10-investment-news-chips-infra-biotech)